concerns about the enormous responsibilities of dr richard sykes glaxo's research and development director and recently appointed chief executive were partly met yesterday when dr goran ando was appointed r d director of glaxo group research the uk research arm and the company's largest research arm analysts had believed that it was impossible for one man to cope as chief executive and be responsible for r d glaxo last year spent nearly pounds 600 m on r d more than any other pharmaceutical company it has research sites in the uk us italy france and spain and employs more than 6,800 r d specialists dr ando who joined glaxo in 1989 as medical director was made deputy r d director in march last year he was responsible for co-ordinating all development medical and regulatory functions in the company's international pharmaceutical development programmes he retains responsibility for world-wide drug development a 44-year-old swede dr ando was previously at astra the swedish group where he was president of the group research centre before that he held positions at pfizer and bristol-myers dr sykes retains the chairmanship of glaxo group research as well as responsibility for r d on the glaxo board